Phathom Pharmaceuticals Inc (NASDAQ: PHAT) kicked off on Tuesday, up 4.16% from the previous trading day, before settling in for the closing price of $8.66. Over the past 52 weeks, PHAT has traded in a range of $2.21-$19.71.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 12.50% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 42.39%. With a float of $37.85 million, this company’s outstanding shares have now reached $69.64 million.
In an organization with 427 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 86.23%, operating margin of -349.84%, and the pretax margin is -307.2%.
Phathom Pharmaceuticals Inc (PHAT) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Phathom Pharmaceuticals Inc is 45.79%, while institutional ownership is 47.35%. The most recent insider transaction that took place on May 21 ’25, was worth 14,609. In this transaction Director of this company bought 3,780 shares at a rate of $3.86, taking the stock ownership to the 59,403 shares. Before that another transaction happened on May 14 ’25, when Company’s Director bought 6,300 for $3.32, making the entire transaction worth $20,919. This insider now owns 55,623 shares in total.
Phathom Pharmaceuticals Inc (PHAT) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 42.39% per share during the next fiscal year.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Trading Performance Indicators
Take a look at Phathom Pharmaceuticals Inc’s (PHAT) current performance indicators. Last quarter, stock had a quick ratio of 3.54. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.69.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.24, a number that is poised to hit -0.91 in the next quarter and is forecasted to reach -0.40 in one year’s time.
Technical Analysis of Phathom Pharmaceuticals Inc (PHAT)
Let’s dig in a bit further. During the last 5-days, its volume was 1.17 million. That was inferior than the volume of 1.95 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 29.04%.
During the past 100 days, Phathom Pharmaceuticals Inc’s (PHAT) raw stochastic average was set at 67.36%, which indicates a significant increase from 27.48% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.73 in the past 14 days, which was higher than the 0.66 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.21, while its 200-day Moving Average is $8.53. However, in the short run, Phathom Pharmaceuticals Inc’s stock first resistance to watch stands at $9.27. Second resistance stands at $9.51. The third major resistance level sits at $9.83. If the price goes on to break the first support level at $8.70, it is likely to go to the next support level at $8.38. Assuming the price breaks the second support level, the third support level stands at $8.14.
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Key Stats
The company with the Market Capitalisation of 629.72 million has total of 69,814K Shares Outstanding. Its annual sales at the moment are 55,250 K in contrast with the sum of -334,330 K annual income. Company’s last quarter sales were recorded 28,520 K and last quarter income was -94,320 K.
